metformin Indications/Contra | FAERs | Orange Book | BioActivity |

Stem definitionDrug idCAS RN
antihyperglycaemics, phenformin derivatives 1725 657-24-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • metformin
  • metformin hydrochloride
  • glucophage
  • LA-6023
  • LA 6023
  • N,N-dimethylguanylguanidine
  • metformin HCl
A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
  • Molecular weight: 129.17
  • Formula: C4H11N5
  • CLOGP: -1.43
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 4
  • TPSA: 88.99
  • ALOGS: -1.97
  • ROTB: 0

Drug dosage:

DoseUnitRoute
2 g O

Approvals:

DateAgencyCompanyOrphan
March 3, 1995 FDA BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lactic acidosis 40154.33 28.98 7513 29107 4443 4597929
Acute kidney injury 18720.56 28.98 5708 30912 64723 4537649
Hypoglycaemia 10177.43 28.98 2670 33950 15739 4586633
Metabolic acidosis 8070.92 28.98 2053 34567 10387 4591985
Toxicity to various agents 5740.15 28.98 2420 34200 69620 4532752
Completed suicide 5575.11 28.98 2050 34570 40395 4561977
Diarrhoea 4963.97 28.98 2757 33863 147428 4454944
Hyperkalaemia 4492.61 28.98 1369 35251 14468 4587904
Vomiting 3748.15 28.98 2127 34493 117572 4484800
Blood glucose increased 3261.85 28.98 1195 35425 23009 4579363
Renal failure 3138.82 28.98 1348 35272 40021 4562351
Hypotension 3075.85 28.98 1543 35077 65857 4536515
Intentional overdose 2840.30 28.98 1050 35570 20716 4581656
Diabetes mellitus inadequate control 2521.54 28.98 648 35972 3361 4599011
Shock 2207.77 28.98 696 35924 8220 4594152
Overdose 2150.00 28.98 1054 35566 42505 4559867
Nausea 2131.05 28.98 1746 34874 175587 4426785
Dehydration 1849.20 28.98 943 35677 41347 4561025
Hyperglycaemia 1625.56 28.98 587 36033 10735 4591637
Diabetic ketoacidosis 1601.03 28.98 525 36095 7075 4595297
Anuria 1586.60 28.98 450 36170 3565 4598807
Haemodialysis 1546.92 28.98 461 36159 4426 4597946
Blood creatinine increased 1525.59 28.98 717 35903 26183 4576189
Suicide attempt 1499.77 28.98 656 35964 20186 4582186
Glycosylated haemoglobin increased 1490.95 28.98 430 36190 3639 4598733
Hyperlactacidaemia 1473.46 28.98 316 36304 580 4601792
Pancreatitis acute 1429.92 28.98 498 36122 8145 4594227
Abdominal pain 1400.78 28.98 888 35732 59136 4543236
Hypoglycaemic coma 1302.56 28.98 301 36319 894 4601478
Blood lactic acid increased 1259.71 28.98 322 36298 1620 4600752
Drug level increased 1246.51 28.98 415 36205 5871 4596501
Hypothermia 1225.95 28.98 375 36245 3959 4598413
Drug interaction 1214.86 28.98 835 35785 63673 4538699
Cardiac arrest 1194.57 28.98 656 35964 33351 4569021
Renal impairment 1102.41 28.98 564 36056 24774 4577598
Exposure during pregnancy 1067.61 28.98 603 36017 32368 4570004
Confusional state 1060.25 28.98 691 35929 48143 4554229
Multiple organ dysfunction syndrome 1028.75 28.98 489 36131 18267 4584105
Pancreatitis 985.50 28.98 462 36158 16716 4585656
Coma 982.98 28.98 464 36156 17055 4585317
Drug hypersensitivity 947.98 28.98 736 35884 67664 4534708
Foetal exposure during pregnancy 860.17 28.98 464 36156 22705 4579667
Acidosis 846.53 28.98 267 36353 3139 4599233
Malaise 836.71 28.98 770 35850 89387 4512985
Asthenia 832.98 28.98 753 35867 85410 4516962
Ketoacidosis 826.31 28.98 231 36389 1720 4600652
Dyspnoea 816.37 28.98 927 35693 138058 4464314
Diabetic metabolic decompensation 807.38 28.98 166 36454 218 4602154
Bradycardia 793.39 28.98 436 36184 22133 4580239
Weight decreased 775.66 28.98 596 36024 53868 4548504
Pemphigoid 728.49 28.98 218 36402 2118 4600254
Tachypnoea 712.93 28.98 257 36363 4654 4597718
Continuous haemodiafiltration 699.04 28.98 162 36458 488 4601884
Blood glucose decreased 690.00 28.98 263 36357 5602 4596770
Cardio-respiratory arrest 680.25 28.98 377 36243 19445 4582927
Somnolence 679.44 28.98 504 36116 43156 4559216
Vitamin B12 deficiency 675.42 28.98 172 36448 848 4601524
Anion gap increased 667.81 28.98 155 36465 471 4601901
Decreased appetite 602.13 28.98 522 36098 55875 4546497
Drug ineffective 594.43 28.98 921 35699 185140 4417232
Gastrointestinal disorder 579.98 28.98 316 36304 15745 4586627
Sopor 556.37 28.98 232 36388 6294 4596078
Maternal exposure during pregnancy 548.04 28.98 311 36309 16782 4585590
Loss of consciousness 517.26 28.98 395 36225 35287 4567085
Abdominal pain upper 516.25 28.98 392 36228 34723 4567649
Poisoning 514.72 28.98 214 36406 5760 4596612
Abdominal discomfort 487.08 28.98 348 36272 28060 4574312
Diabetes mellitus 475.34 28.98 274 36346 15227 4587145
Pancreatic carcinoma 468.22 28.98 173 36447 3366 4599006
Depressed level of consciousness 465.03 28.98 268 36352 14886 4587486
Haemodynamic instability 464.72 28.98 161 36459 2578 4599794
Respiratory failure 462.22 28.98 346 36274 29980 4572392
Hypovolaemia 461.96 28.98 159 36461 2494 4599878
Blood bicarbonate decreased 461.43 28.98 127 36493 885 4601487
Rhabdomyolysis 458.55 28.98 291 36329 19267 4583105
Tachycardia 458.42 28.98 348 36272 30797 4571575
Blood potassium increased 450.71 28.98 186 36434 4909 4597463
Blood pH decreased 447.16 28.98 125 36495 929 4601443
Weight increased 429.74 28.98 358 36262 36223 4566149
Dizziness 425.75 28.98 568 36052 99303 4503069
Body temperature decreased 422.10 28.98 147 36473 2392 4599980
Dialysis 413.63 28.98 173 36447 4726 4597646
Medication error 410.75 28.98 243 36377 14173 4588199
Hypertension 409.24 28.98 402 36218 50396 4551976
Product complaint 398.23 28.98 193 36427 7501 4594871
Blood glucose abnormal 396.52 28.98 139 36481 2308 4600064
Exposure via ingestion 396.00 28.98 123 36497 1367 4601005
Fall 390.85 28.98 481 36139 77565 4524807
Sepsis 390.50 28.98 363 36257 42476 4559896
Unresponsive to stimuli 387.73 28.98 207 36413 9886 4592486
Anaemia 382.69 28.98 456 36164 71104 4531268
Hyperhidrosis 381.13 28.98 307 36313 29610 4572762
Gastroenteritis 379.81 28.98 169 36451 5386 4596986
Condition aggravated 375.95 28.98 409 36211 57762 4544610
Hepatic steatosis 373.74 28.98 173 36447 6055 4596317
Product residue present 363.82 28.98 129 36491 2218 4600154
Blood glucose fluctuation 360.66 28.98 115 36505 1401 4600971
Syncope 359.72 28.98 311 36309 33084 4569288
Leukocytosis 354.90 28.98 178 36442 7456 4594916
Drug-induced liver injury 343.55 28.98 181 36439 8410 4593962
Intentional product misuse 341.08 28.98 237 36383 18256 4584116
Fatigue 334.03 28.98 623 35997 144943 4457429
Headache 333.78 28.98 565 36055 121808 4480564
Premature baby 327.72 28.98 185 36435 9866 4592506
Renal tubular necrosis 322.86 28.98 137 36483 3881 4598491
Circulatory collapse 319.78 28.98 167 36453 7618 4594754
Oliguria 317.85 28.98 122 36498 2645 4599727
Hepatitis 312.16 28.98 192 36428 12013 4590359
General physical health deterioration 305.81 28.98 266 36354 28512 4573860
Hypomagnesaemia 304.16 28.98 142 36478 5067 4597305
Blood pressure decreased 301.37 28.98 217 36403 17683 4584689
Hypokalaemia 299.00 28.98 220 36400 18540 4583832
Atrial fibrillation 291.06 28.98 268 36352 30947 4571425
Cardiogenic shock 290.18 28.98 139 36481 5259 4597113
PCO2 decreased 285.94 28.98 78 36542 523 4601849
Cardiac failure 281.44 28.98 248 36372 27040 4575332
Blood urea increased 268.99 28.98 155 36465 8595 4593777
Base excess decreased 268.83 28.98 55 36565 69 4602303
Poisoning deliberate 267.95 28.98 102 36518 2160 4600212
Agitation 267.86 28.98 229 36391 23971 4578401
Death 265.62 28.98 683 35937 197480 4404892
Hyponatraemia 265.57 28.98 230 36390 24500 4577872
Euglycaemic diabetic ketoacidosis 263.90 28.98 67 36553 325 4602047
Disorientation 263.87 28.98 174 36446 12285 4590087
Mental status changes 260.07 28.98 172 36448 12204 4590168
Chest pain 259.17 28.98 316 36304 50384 4551988
Pruritus 258.42 28.98 379 36241 72193 4530179
Urinary tract infection 252.87 28.98 286 36334 42104 4560268
Inappropriate schedule of product administration 252.31 28.98 214 36406 22156 4580216
Polyuria 251.16 28.98 102 36518 2578 4599794
Pancreatic carcinoma metastatic 250.41 28.98 82 36538 1093 4601279
Glomerular filtration rate decreased 249.40 28.98 108 36512 3218 4599154
Hepatic failure 245.88 28.98 170 36450 12979 4589393
Blood pressure increased 244.18 28.98 237 36383 29223 4573149
Acute myocardial infarction 242.71 28.98 175 36445 14284 4588088
Jaundice 242.05 28.98 165 36455 12309 4590063
Hepatotoxicity 241.83 28.98 142 36478 8157 4594215
Blood pressure systolic increased 240.92 28.98 114 36506 4194 4598178
Amylase increased 235.90 28.98 97 36523 2533 4599839
Type 2 diabetes mellitus 232.76 28.98 111 36509 4156 4598216
Accidental overdose 232.58 28.98 144 36476 9111 4593261
Drug intolerance 230.95 28.98 201 36419 21545 4580827
Myocardial infarction 228.76 28.98 293 36327 49083 4553289
Diabetic neuropathy 228.36 28.98 74 36546 952 4601420
Premature delivery 225.67 28.98 108 36512 4076 4598296
Product prescribing error 225.42 28.98 129 36491 7057 4595315
Hepatocellular injury 224.49 28.98 133 36487 7767 4594605
Product use in unapproved indication 222.08 28.98 210 36410 25063 4577309
Septic shock 215.37 28.98 173 36447 16593 4585779
Pulseless electrical activity 215.23 28.98 86 36534 2081 4600291
Chronic kidney disease 211.75 28.98 143 36477 10502 4591870
Coma scale abnormal 208.26 28.98 77 36543 1499 4600873
Hypocapnia 208.15 28.98 49 36571 161 4602211
Hemiplegia 207.04 28.98 91 36529 2812 4599560
Heart rate increased 206.24 28.98 176 36444 18366 4584006
Electrocardiogram QT prolonged 205.39 28.98 162 36458 15133 4587239
Respiratory distress 203.79 28.98 142 36478 10974 4591398
Pyrexia 203.41 28.98 424 36196 106720 4495652
Adverse drug reaction 201.99 28.98 158 36462 14581 4587791
Blood sodium decreased 201.98 28.98 111 36509 5611 4596761
Haemolytic anaemia 201.76 28.98 100 36520 4078 4598294
Sinus tachycardia 201.16 28.98 114 36506 6120 4596252
Dyspepsia 200.59 28.98 163 36457 15891 4586481
Product substitution issue 199.39 28.98 131 36489 9187 4593185
Thrombocytopenia 199.29 28.98 269 36351 47404 4554968
Cholestasis 198.42 28.98 123 36497 7797 4594575
Diabetic nephropathy 198.25 28.98 58 36562 516 4601856
Respiratory arrest 197.32 28.98 150 36470 13270 4589102
Dysarthria 197.29 28.98 145 36475 12187 4590185
Bladder cancer 195.07 28.98 89 36531 3008 4599364
Blood chloride decreased 193.28 28.98 70 36550 1282 4601090
Alanine aminotransferase increased 192.67 28.98 205 36415 28168 4574204
Hypophagia 190.75 28.98 119 36501 7629 4594743
Myalgia 189.20 28.98 246 36374 41802 4560570
Encephalopathy 188.76 28.98 130 36490 9857 4592515
Lethargy 188.38 28.98 162 36458 17079 4585293
Oedema peripheral 180.25 28.98 240 36380 41732 4560640
Hyperventilation 180.10 28.98 73 36547 1835 4600537
Pneumonia 179.12 28.98 393 36227 102422 4499950
Lipase increased 178.69 28.98 86 36534 3286 4599086
Vasoplegia syndrome 177.67 28.98 49 36571 344 4602028
Urticaria 172.57 28.98 228 36392 39345 4563027
Respiratory rate increased 171.60 28.98 80 36540 2843 4599529
Cough 167.69 28.98 269 36351 55318 4547054
Hepatitis acute 166.75 28.98 79 36541 2913 4599459
Pharyngitis 166.58 28.98 84 36536 3555 4598817
Altered state of consciousness 165.54 28.98 110 36510 7861 4594511
Vitamin B12 decreased 163.49 28.98 50 36570 525 4601847
Presyncope 161.52 28.98 103 36517 6861 4595511
Hypovolaemic shock 161.32 28.98 67 36553 1795 4600577
Aspartate aminotransferase increased 158.46 28.98 174 36446 24764 4577608
Gait inability 157.44 28.98 115 36505 9570 4592802
Drug abuse 155.50 28.98 182 36438 27765 4574607
Cholelithiasis 153.66 28.98 112 36508 9290 4593082
Caesarean section 153.17 28.98 89 36531 5009 4597363
Hypoglycaemia neonatal 152.08 28.98 49 36571 618 4601754
Lower respiratory tract infection 151.89 28.98 114 36506 9889 4592483
Ventricular tachycardia 151.42 28.98 101 36519 7263 4595109
Abdominal distension 151.38 28.98 146 36474 17843 4584529
Renal injury 151.13 28.98 71 36549 2568 4599804
Electrolyte imbalance 151.12 28.98 80 36540 3749 4598623
Blood lactic acid 150.08 28.98 29 36591 20 4602352
Eosinophilia 148.84 28.98 98 36522 6895 4595477
Aphasia 147.89 28.98 107 36513 8773 4593599
Acute respiratory distress syndrome 147.19 28.98 100 36520 7413 4594959
Blood pressure diastolic decreased 146.37 28.98 63 36557 1848 4600524
Angioedema 145.23 28.98 149 36471 19616 4582756
Diabetic retinopathy 143.95 28.98 48 36572 679 4601693
Adenocarcinoma pancreas 143.56 28.98 45 36575 516 4601856
Blood phosphorus increased 143.15 28.98 50 36570 820 4601552
Muscular weakness 142.90 28.98 170 36450 26380 4575992
Urosepsis 142.75 28.98 76 36544 3603 4598769
Gastrooesophageal reflux disease 140.90 28.98 129 36491 14764 4587608
Incorrect dose administered 140.38 28.98 145 36475 19240 4583132
Product odour abnormal 140.03 28.98 48 36572 742 4601630
Ventricular fibrillation 139.06 28.98 85 36535 5252 4597120
Cold sweat 138.97 28.98 77 36543 3954 4598418
Pancreatitis chronic 137.66 28.98 45 36575 596 4601776
Back pain 136.62 28.98 233 36387 50366 4552006
Prerenal failure 136.01 28.98 43 36577 508 4601864
Tubulointerstitial nephritis 135.72 28.98 88 36532 6031 4596341
Blood creatine phosphokinase increased 135.52 28.98 127 36493 14972 4587400
Creatinine renal clearance decreased 134.49 28.98 59 36561 1814 4600558
Arthralgia 134.35 28.98 306 36314 81688 4520684
Low birth weight baby 134.22 28.98 66 36554 2644 4599728
Anion gap 133.81 28.98 35 36585 195 4602177
Treatment noncompliance 133.37 28.98 114 36506 11913 4590459
Hypocalcaemia 132.74 28.98 96 36524 7865 4594507
Product administration error 131.57 28.98 97 36523 8187 4594185
White blood cell count increased 130.51 28.98 125 36495 15142 4587230
Live birth 129.93 28.98 54 36566 1449 4600923
Constipation 129.82 28.98 206 36414 41948 4560424
Toothache 129.29 28.98 72 36548 3734 4598638
Vertigo 128.89 28.98 123 36497 14833 4587539
Pancytopenia 126.98 28.98 155 36465 24698 4577674
Persistent cloaca 126.55 28.98 23 36597 5 4602367
Pneumonia aspiration 126.41 28.98 101 36519 9605 4592767
Anaemia vitamin B12 deficiency 125.54 28.98 30 36590 107 4602265
Atrioventricular block complete 125.47 28.98 66 36554 3052 4599320
Coagulopathy 125.22 28.98 84 36536 6096 4596276
Erythema 125.11 28.98 202 36418 41738 4560634
Cardiopulmonary failure 124.50 28.98 55 36565 1720 4600652
Muscle spasms 124.15 28.98 184 36436 35306 4567066
Microalbuminuria 124.14 28.98 35 36585 269 4602103
PO2 increased 123.57 28.98 35 36585 274 4602098
Arrhythmia 122.99 28.98 115 36505 13517 4588855
Pulmonary fibrosis 122.50 28.98 80 36540 5550 4596822
Polydipsia 121.49 28.98 51 36569 1404 4600968
Atrial septal defect 121.25 28.98 67 36553 3422 4598950
Conjoined twins 119.67 28.98 24 36596 25 4602347
Acetonaemia 119.41 28.98 25 36595 38 4602334
Rash 119.10 28.98 348 36272 108040 4494332
Dysphagia 118.88 28.98 152 36468 25379 4576993
Pallor 118.55 28.98 88 36532 7504 4594868
Interstitial lung disease 118.08 28.98 132 36488 19153 4583219
Hypoaesthesia 117.76 28.98 169 36451 31496 4570876
Neutrophilia 117.39 28.98 47 36573 1143 4601229
Mitral valve incompetence 117.33 28.98 73 36547 4655 4597717
Ischaemic stroke 116.71 28.98 87 36533 7467 4594905
Cardiovascular disorder 116.26 28.98 78 36542 5662 4596710
Distributive shock 115.49 28.98 32 36588 229 4602143
Drug level above therapeutic 114.91 28.98 46 36574 1118 4601254
Latent autoimmune diabetes in adults 114.83 28.98 24 36596 36 4602336
Electrocardiogram QRS complex prolonged 114.19 28.98 54 36566 1982 4600390
Gait disturbance 114.11 28.98 180 36440 36460 4565912
Gamma-glutamyltransferase increased 113.37 28.98 101 36519 11153 4591219
Cerebrovascular accident 111.50 28.98 192 36428 41808 4560564
Postprandial hypoglycaemia 107.26 28.98 20 36600 8 4602364
Contraindicated product administered 106.74 28.98 71 36549 5080 4597292
Ketonuria 106.33 28.98 31 36589 272 4602100
Tremor 105.89 28.98 173 36447 36086 4566286
Metastases to liver 105.55 28.98 73 36547 5569 4596803
Systemic infection 104.87 28.98 28 36592 171 4602201
Personality disorder 104.42 28.98 37 36583 634 4601738
Flatulence 104.28 28.98 84 36536 8080 4594292
Abortion spontaneous 104.26 28.98 107 36513 14085 4588287
Azotaemia 104.05 28.98 46 36574 1441 4600931
Basilar artery thrombosis 103.10 28.98 24 36596 74 4602298
Respiratory disorder 102.54 28.98 82 36538 7806 4594566
Product quality issue 102.09 28.98 125 36495 19974 4582398
Renal cyst 101.80 28.98 52 36568 2261 4600111
Intentional self-injury 100.80 28.98 79 36541 7304 4595068
Kussmaul respiration 100.56 28.98 24 36596 85 4602287
Abdominal tenderness 100.00 28.98 47 36573 1701 4600671
Haemoglobin decreased 99.75 28.98 172 36448 37485 4564887
Metabolic disorder 99.71 28.98 44 36576 1372 4601000
Systemic inflammatory response syndrome 99.45 28.98 48 36572 1845 4600527
Vision blurred 99.07 28.98 137 36483 24666 4577706
Dyslipidaemia 98.12 28.98 46 36574 1655 4600717
Blindness 97.91 28.98 77 36543 7155 4595217
Nephrolithiasis 96.81 28.98 84 36536 8955 4593417
Myocardial ischaemia 95.73 28.98 70 36550 5832 4596540
Hepatic cirrhosis 95.51 28.98 68 36552 5434 4596938
No adverse event 95.47 28.98 127 36493 22036 4580336
Hepatitis cholestatic 95.37 28.98 52 36568 2586 4599786
Obesity 95.05 28.98 53 36567 2755 4599617
Anal incontinence 94.95 28.98 55 36565 3076 4599296
Haematemesis 94.76 28.98 83 36537 8960 4593412
Palpitations 94.42 28.98 134 36486 24712 4577660
Wrong product administered 94.33 28.98 56 36564 3279 4599093
Left atrial dilatation 92.45 28.98 32 36588 510 4601862
Hypoperfusion 92.16 28.98 31 36589 451 4601921
Intestinal malrotation 92.16 28.98 22 36598 78 4602294
Pollakiuria 92.10 28.98 74 36546 7091 4595281
Liver injury 92.08 28.98 64 36556 4921 4597451
Hyperthyroidism 91.94 28.98 59 36561 3971 4598401
Hypersensitivity vasculitis 91.92 28.98 51 36569 2625 4599747
Gastric ulcer 91.21 28.98 69 36551 6054 4596318
Diabetic foot infection 91.20 28.98 25 36595 171 4602201
Pulmonary oedema 90.74 28.98 102 36518 14884 4587488
Discomfort 89.02 28.98 77 36543 8173 4594199
Transaminases increased 88.50 28.98 82 36538 9524 4592848
Off label use 88.42 28.98 354 36266 128759 4473613
Blindness transient 88.41 28.98 43 36577 1681 4600691
Hemiparesis 87.70 28.98 69 36551 6415 4595957
Bradyphrenia 87.57 28.98 44 36576 1847 4600525
Urine albumin/creatinine ratio abnormal 87.24 28.98 17 36603 13 4602359
Urine output decreased 86.97 28.98 52 36568 3085 4599287
Bundle branch block right 86.57 28.98 46 36574 2171 4600201
Adverse event 86.07 28.98 103 36517 16069 4586303
Hypersensitivity 85.85 28.98 163 36457 38258 4564114
Anaemia macrocytic 85.80 28.98 34 36586 804 4601568
Product dispensing error 85.46 28.98 66 36554 5971 4596401
Asthma 84.93 28.98 106 36514 17268 4585104
Agranulocytosis 84.86 28.98 72 36548 7445 4594927
Dysentery 84.64 28.98 27 36593 329 4602043
Electrocardiogram T wave peaked 83.84 28.98 24 36596 196 4602176
Foetal disorder 83.67 28.98 26 36594 289 4602083
Hepatic enzyme increased 83.56 28.98 107 36513 17884 4584488
Haematuria 83.22 28.98 91 36529 12879 4589493
Cognitive disorder 82.43 28.98 82 36538 10399 4591973
Chest discomfort 82.09 28.98 121 36499 23089 4579283
Retching 82.01 28.98 52 36568 3427 4598945
Toxic epidermal necrolysis 81.83 28.98 65 36555 6127 4596245
Gastritis 81.52 28.98 73 36547 8113 4594259
Heart rate decreased 81.32 28.98 68 36552 6892 4595480
Intestinal ischaemia 81.07 28.98 45 36575 2318 4600054
Paraesthesia 80.92 28.98 151 36469 34982 4567390
Head injury 79.59 28.98 69 36551 7346 4595026
Anhidrosis 79.28 28.98 20 36600 94 4602278
Delirium 79.27 28.98 88 36532 12664 4589708
Left ventricular hypertrophy 78.15 28.98 39 36581 1613 4600759
Proteinuria 77.88 28.98 65 36555 6571 4595801
Hypoventilation 77.34 28.98 36 36584 1274 4601098
Tricuspid valve incompetence 77.06 28.98 48 36572 3066 4599306
Hypoglycaemic encephalopathy 76.82 28.98 21 36599 142 4602230
Brain injury 76.80 28.98 42 36578 2101 4600271
Naevus flammeus 76.26 28.98 18 36602 60 4602312
Large for dates baby 76.03 28.98 24 36596 282 4602090
Cerebral ischaemia 75.97 28.98 44 36576 2460 4599912
Cardiometabolic syndrome 75.90 28.98 29 36591 620 4601752
Dry mouth 75.64 28.98 87 36533 13014 4589358
Liver function test abnormal 75.62 28.98 92 36528 14600 4587772
Therapeutic response unexpected 75.48 28.98 65 36555 6857 4595515
Product dose omission 75.36 28.98 217 36403 66745 4535627
Melaena 74.81 28.98 76 36544 9882 4592490
Anaemia megaloblastic 74.18 28.98 21 36599 164 4602208
Blood magnesium decreased 73.17 28.98 41 36579 2151 4600221
Fournier's gangrene 72.80 28.98 22 36598 221 4602151
Cardiac failure congestive 72.72 28.98 139 36481 32783 4569589
Speech disorder 72.23 28.98 80 36540 11482 4590890
Oedema 71.04 28.98 101 36519 18650 4583722
Toe amputation 70.72 28.98 30 36590 848 4601524
Diabetic ketoacidotic hyperglycaemic coma 70.63 28.98 17 36603 63 4602309
Acute coronary syndrome 70.27 28.98 51 36569 4199 4598173
Malabsorption 70.27 28.98 33 36587 1192 4601180
Urachal abnormality 70.09 28.98 14 36606 14 4602358
Cholestatic liver injury 69.82 28.98 27 36593 597 4601775
Thirst 69.82 28.98 45 36575 3051 4599321
Toxic encephalopathy 69.81 28.98 37 36583 1737 4600635
Duodenal ulcer 69.37 28.98 45 36575 3085 4599287
Potentiating drug interaction 69.28 28.98 35 36585 1486 4600886
Fixed eruption 68.91 28.98 25 36595 460 4601912
Gastrointestinal sounds abnormal 68.55 28.98 31 36589 1025 4601347
Pain in extremity 68.31 28.98 203 36417 63536 4538836
Acid base balance abnormal 68.27 28.98 17 36603 75 4602297
Pyelonephritis acute 68.19 28.98 29 36591 825 4601547
Glycosylated haemoglobin decreased 68.11 28.98 21 36599 227 4602145
Small for dates baby 67.90 28.98 38 36582 1989 4600383
Seizure 67.71 28.98 174 36446 50063 4552309
Anxiety 67.53 28.98 169 36451 47842 4554530
Nervous system disorder 67.32 28.98 59 36561 6372 4596000
Polyhydramnios 67.21 28.98 24 36596 421 4601951
Depression 67.12 28.98 168 36452 47565 4554807
Nephropathy toxic 66.78 28.98 49 36571 4103 4598269
Dysuria 66.65 28.98 65 36555 8045 4594327
Anion gap abnormal 66.36 28.98 17 36603 86 4602286
Congestive cardiomyopathy 66.17 28.98 39 36581 2253 4600119
Mydriasis 66.17 28.98 47 36573 3741 4598631
Patent ductus arteriosus 66.12 28.98 35 36585 1639 4600733
Glycosuria 65.71 28.98 25 36595 528 4601844
Sinus bradycardia 64.75 28.98 49 36571 4300 4598072
Pancreaticoduodenectomy 64.54 28.98 16 36604 69 4602303
Bile duct stent insertion 64.21 28.98 17 36603 100 4602272
Neuropathy peripheral 63.82 28.98 109 36511 23560 4578812
Neutropenia neonatal 63.81 28.98 16 36604 73 4602299
Renal aplasia 63.56 28.98 21 36599 288 4602084
Insulin C-peptide decreased 63.47 28.98 14 36606 31 4602341
Pancreatic failure 63.37 28.98 21 36599 291 4602081
Rectal haemorrhage 63.28 28.98 77 36543 12219 4590153
Osteomyelitis 63.08 28.98 56 36564 6152 4596220
Feeling abnormal 63.02 28.98 139 36481 36266 4566106
Pulmonary embolism 62.51 28.98 134 36486 34292 4568080
Resuscitation 62.50 28.98 26 36594 699 4601673
Blood potassium decreased 62.17 28.98 62 36558 7884 4594488
Blood triglycerides increased 62.15 28.98 52 36568 5273 4597099
Bronchitis 61.73 28.98 98 36522 19942 4582430
Hypernatraemia 61.73 28.98 36 36584 2039 4600333
Hyperlipidaemia 61.63 28.98 51 36569 5094 4597278
Drug reaction with eosinophilia and systemic symptoms 61.34 28.98 74 36546 11639 4590733
Blindness cortical 61.32 28.98 19 36601 209 4602163
Impaired work ability 61.06 28.98 41 36579 2979 4599393
Oxygen saturation decreased 60.92 28.98 81 36539 14040 4588332
Diabetic foetopathy 60.87 28.98 13 36607 23 4602349
Hypoxia 60.86 28.98 78 36542 13043 4589329
Base excess negative 60.51 28.98 13 36607 24 4602348
Urine ketone body present 60.50 28.98 24 36596 569 4601803
Gout 60.14 28.98 47 36573 4326 4598046
Toxic skin eruption 60.07 28.98 47 36573 4333 4598039
Maternal drugs affecting foetus 59.76 28.98 45 36575 3920 4598452
Disseminated intravascular coagulation 59.75 28.98 59 36561 7414 4594958
Ketosis 59.45 28.98 19 36601 233 4602139
International normalised ratio increased 59.25 28.98 88 36532 16900 4585472
Bundle branch block left 59.21 28.98 34 36586 1870 4600502
Pain 59.04 28.98 249 36371 92621 4509751
Renal disorder 58.67 28.98 65 36555 9331 4593041
Congenital bladder anomaly 58.37 28.98 15 36605 77 4602295
Insomnia 57.97 28.98 154 36466 45191 4557181
Deep vein thrombosis 57.97 28.98 109 36511 25385 4576987
Metastases to peritoneum 57.63 28.98 26 36594 855 4601517
Nephropathy 57.40 28.98 34 36586 1982 4600390
Cardiovascular insufficiency 57.32 28.98 24 36596 656 4601716
Foetal death 57.32 28.98 37 36583 2515 4599857
Foetal macrosomia 57.13 28.98 15 36605 85 4602287
Acute lung injury 56.73 28.98 21 36599 410 4601962
Overweight 56.69 28.98 25 36595 778 4601594
Hypertensive heart disease 56.69 28.98 26 36594 889 4601483
Pregnancy 56.64 28.98 62 36558 8782 4593590
Mucosal dryness 56.44 28.98 23 36597 586 4601786
Acute abdomen 56.36 28.98 24 36596 685 4601687
Swelling face 56.31 28.98 80 36540 14760 4587612
Urinary retention 56.18 28.98 65 36555 9782 4592590
Respiratory acidosis 55.97 28.98 31 36589 1590 4600782
Coordination abnormal 55.96 28.98 42 36578 3640 4598732
Hypoplastic left heart syndrome 55.93 28.98 18 36602 226 4602146
Blister 55.89 28.98 70 36550 11439 4590933
Dysstasia 55.89 28.98 47 36573 4800 4597572
Haemofiltration 55.86 28.98 13 36607 40 4602332
Cerebral venous thrombosis 55.84 28.98 24 36596 701 4601671
Anaphylactic reaction 55.74 28.98 88 36532 17822 4584550
Blood cholesterol increased 55.70 28.98 61 36559 8645 4593727
Bradykinesia 55.31 28.98 28 36592 1194 4601178
Respiratory alkalosis 55.23 28.98 23 36597 620 4601752
Arteriosclerosis 53.63 28.98 40 36580 3434 4598938
Colitis microscopic 53.61 28.98 29 36591 1419 4600953
Large intestine polyp 53.40 28.98 34 36586 2257 4600115
Cerebral haematoma 53.38 28.98 29 36591 1431 4600941
Eating disorder 53.37 28.98 41 36579 3679 4598693
Hypoglycaemic unconsciousness 52.90 28.98 20 36600 415 4601957
Coma acidotic 52.83 28.98 12 36608 32 4602340
Blood alkaline phosphatase increased 52.82 28.98 71 36549 12436 4589936
Cardiorenal syndrome 52.74 28.98 16 36604 163 4602209
Dyspnoea exertional 52.33 28.98 64 36556 10208 4592164
Skin turgor decreased 52.31 28.98 16 36604 168 4602204
Self-medication 52.18 28.98 28 36592 1348 4601024
Superinfection 52.12 28.98 22 36598 614 4601758
Genital infection fungal 51.93 28.98 18 36602 288 4602084
Cerebral haemorrhage 51.79 28.98 73 36547 13368 4589004
Liver disorder 51.76 28.98 72 36548 13026 4589346
Hepatorenal syndrome 51.44 28.98 24 36596 854 4601518
Cholecystitis 51.33 28.98 42 36578 4129 4598243
Neurologic neglect syndrome 51.21 28.98 15 36605 134 4602238
Premature rupture of membranes 51.19 28.98 25 36595 986 4601386
Congenital uterine anomaly 50.63 28.98 11 36609 22 4602350
Visual impairment 50.34 28.98 88 36532 19372 4583000
Abdominal pain lower 49.90 28.98 42 36578 4294 4598078
Foetal growth restriction 49.88 28.98 34 36586 2532 4599840
Congenital cystic kidney disease 49.82 28.98 17 36603 259 4602113
Prescription drug used without a prescription 49.73 28.98 20 36600 492 4601880
Pulmonary hypertension 49.65 28.98 57 36563 8506 4593866
Fungal infection 49.53 28.98 55 36565 7914 4594458
Gestational diabetes 49.43 28.98 28 36592 1500 4600872
Oesophageal perforation 49.22 28.98 17 36603 269 4602103
Pulse abnormal 49.19 28.98 21 36599 603 4601769
Blood bilirubin increased 49.18 28.98 69 36551 12583 4589789
Pleural effusion 49.00 28.98 99 36521 24299 4578073
Autoimmune haemolytic anaemia 48.72 28.98 29 36591 1706 4600666
Gastric disorder 48.07 28.98 47 36573 5835 4596537
Benign prostatic hyperplasia 48.04 28.98 27 36593 1425 4600947
Balance disorder 48.02 28.98 78 36542 16178 4586194
Sudden death 47.95 28.98 45 36575 5310 4597062
Non-alcoholic steatohepatitis 47.90 28.98 18 36602 367 4602005
Prescribed overdose 47.04 28.98 39 36581 3905 4598467
Bile duct stenosis 46.88 28.98 19 36601 477 4601895
Coronary artery disease 46.68 28.98 77 36543 16175 4586197
Allergic reaction to excipient 46.56 28.98 13 36607 96 4602276
Ascites 46.52 28.98 66 36554 12159 4590213
Rash maculo-papular 46.49 28.98 55 36565 8474 4593898
Congenital hydrocephalus 46.42 28.98 15 36605 191 4602181
Hyperglycaemic hyperosmolar nonketotic syndrome 46.16 28.98 17 36603 327 4602045
Hypokinesia 46.00 28.98 35 36585 3096 4599276
Stress 45.92 28.98 59 36561 9889 4592483
Muscle spasticity 45.79 28.98 36 36584 3342 4599030
Creatinine renal clearance abnormal 45.58 28.98 15 36605 203 4602169
Productive cough 45.30 28.98 57 36563 9356 4593016
Hypercalcaemia 45.18 28.98 42 36578 4896 4597476
Wheezing 45.01 28.98 62 36558 11112 4591260
Dysgeusia 44.99 28.98 72 36548 14747 4587625
Dermatitis exfoliative 44.84 28.98 34 36586 2992 4599380
Antipsychotic drug level decreased 44.80 28.98 15 36605 215 4602157
Myopathy 44.66 28.98 37 36583 3701 4598671
Skinfold measurement 44.65 28.98 8 36612 1 4602371
Angina pectoris 44.50 28.98 57 36563 9524 4592848
Carotid artery thrombosis 44.29 28.98 15 36605 223 4602149
Bradypnoea 43.70 28.98 21 36599 799 4601573
Actinic elastosis 43.67 28.98 10 36610 28 4602344
Hepatic function abnormal 43.63 28.98 70 36550 14366 4588006
Product monitoring error 43.63 28.98 15 36605 234 4602138
Needle issue 43.48 28.98 28 36592 1895 4600477
Rash erythematous 43.37 28.98 59 36561 10450 4591922
Hyperuricaemia 43.18 28.98 27 36593 1736 4600636
Urine output increased 43.15 28.98 19 36601 589 4601783
Jaundice cholestatic 43.14 28.98 26 36594 1565 4600807
Transposition of the great vessels 43.05 28.98 16 36604 316 4602056
Osteoarthritis 42.83 28.98 56 36564 9548 4592824
Hepatomegaly 42.78 28.98 36 36584 3679 4598693
Stupor 42.75 28.98 25 36595 1423 4600949
Pulmonary mass 42.71 28.98 35 36585 3448 4598924
Rales 42.70 28.98 29 36591 2147 4600225
Blood sodium increased 42.59 28.98 22 36598 979 4601393
Ejection fraction decreased 42.56 28.98 43 36577 5553 4596819
Prothrombin consumption time prolonged 42.35 28.98 8 36612 4 4602368
Acute hepatic failure 42.13 28.98 43 36577 5619 4596753
Insulin resistance 42.09 28.98 16 36604 337 4602035
Neutrophil count increased 41.94 28.98 40 36580 4815 4597557
Abnormal loss of weight 41.87 28.98 24 36596 1315 4601057
Oropharyngeal pain 41.82 28.98 76 36544 17243 4585129
Pyelonephritis 41.73 28.98 33 36587 3089 4599283
Hyperoxaluria 41.50 28.98 11 36609 65 4602307
Arteriosclerosis coronary artery 41.34 28.98 33 36587 3131 4599241
Renal tubular disorder 41.20 28.98 25 36595 1523 4600849
Escherichia test positive 41.18 28.98 17 36603 448 4601924
Foetal hypokinesia 41.14 28.98 15 36605 280 4602092
Left ventricular dysfunction 41.02 28.98 31 36589 2714 4599658
Hypoglycaemic seizure 40.99 28.98 15 36605 283 4602089
Neonatal respiratory distress syndrome 40.98 28.98 26 36594 1715 4600657
Diastolic dysfunction 40.80 28.98 23 36597 1221 4601151
Pulmonary hypoplasia 40.70 28.98 15 36605 289 4602083
Hypovitaminosis 40.63 28.98 14 36606 220 4602152
Inappropriate antidiuretic hormone secretion 40.54 28.98 38 36582 4476 4597896
Urine albumin/creatinine ratio increased 40.31 28.98 12 36608 114 4602258
Cardiac murmur 40.21 28.98 32 36588 3023 4599349
Respiratory depression 40.21 28.98 40 36580 5070 4597302
Diarrhoea haemorrhagic 40.14 28.98 30 36590 2583 4599789
Haemolysis 40.12 28.98 30 36590 2585 4599787
Skin lesion 40.11 28.98 48 36572 7485 4594887
Pre-eclampsia 40.06 28.98 25 36595 1602 4600770
Hepatic fibrosis 39.92 28.98 23 36597 1273 4601099
Adjustment disorder 39.86 28.98 15 36605 307 4602065
Base excess 39.62 28.98 9 36611 24 4602348
Alopecia 39.62 28.98 99 36521 27981 4574391
Placental insufficiency 39.55 28.98 15 36605 314 4602058
Ventricular extrasystoles 39.51 28.98 36 36584 4090 4598282
Blood pressure fluctuation 39.34 28.98 35 36585 3855 4598517
Peripheral circulatory failure 39.15 28.98 12 36608 127 4602245
Monoclonal B-cell lymphocytosis 39.10 28.98 9 36611 26 4602346
Corrected transposition of great vessels 38.96 28.98 7 36613 1 4602371
Restlessness 38.84 28.98 53 36567 9416 4592956
Congenital absence of bile ducts 38.60 28.98 9 36611 28 4602344
Aortic valve incompetence 38.60 28.98 25 36595 1709 4600663
Electrocardiogram abnormal 38.43 28.98 30 36590 2756 4599616
Autoimmune pancreatitis 38.40 28.98 12 36608 136 4602236
Obstructive airways disorder 37.86 28.98 29 36591 2591 4599781
Prostatomegaly 37.77 28.98 18 36602 672 4601700
Shock haemorrhagic 37.63 28.98 30 36590 2842 4599530
Wernicke's encephalopathy 37.57 28.98 13 36607 207 4602165
Type I hypersensitivity 37.52 28.98 20 36600 950 4601422
Polyneuropathy 37.43 28.98 34 36586 3847 4598525
Leukaemoid reaction 37.28 28.98 11 36609 101 4602271
Accidental exposure to product by child 37.21 28.98 24 36596 1629 4600743
Disturbance in attention 37.16 28.98 55 36565 10526 4591846
Eczema 37.03 28.98 41 36579 5880 4596492
Bezoar 36.81 28.98 15 36605 382 4601990
Sleep apnoea syndrome 36.77 28.98 36 36584 4475 4597897
Apnoea 36.76 28.98 31 36589 3177 4599195
Diabetic hyperosmolar coma 36.46 28.98 13 36607 227 4602145
Aortitis 36.16 28.98 12 36608 167 4602205
Gangrene 36.13 28.98 23 36597 1526 4600846
Diabetic foot 36.01 28.98 16 36604 507 4601865
Hyperphosphataemia 35.99 28.98 17 36603 622 4601750
Heart disease congenital 35.98 28.98 21 36599 1191 4601181
Radiotherapy 35.97 28.98 14 36606 315 4602057
Pancreatic pseudocyst 35.85 28.98 14 36606 318 4602054
Lipids abnormal 35.79 28.98 13 36607 240 4602132
Anal atresia 35.69 28.98 13 36607 242 4602130
Sputum discoloured 35.69 28.98 25 36595 1946 4600426
Protein urine present 35.59 28.98 22 36598 1386 4600986
Renal ischaemia 35.58 28.98 12 36608 176 4602196
Normal newborn 35.56 28.98 24 36596 1758 4600614
Vitamin B1 decreased 35.55 28.98 9 36611 43 4602329
Escherichia urinary tract infection 35.45 28.98 24 36596 1767 4600605
Weight fluctuation 35.44 28.98 21 36599 1225 4601147
Pancreatic atrophy 35.42 28.98 11 36609 122 4602250
Breath sounds abnormal 35.39 28.98 22 36598 1400 4600972
Swelling 35.26 28.98 87 36533 24395 4577977
Body mass index increased 35.13 28.98 14 36606 336 4602036
HELLP syndrome 35.06 28.98 13 36607 255 4602117
Glucose tolerance impaired 35.04 28.98 20 36600 1087 4601285
Alcohol use 34.88 28.98 22 36598 1436 4600936
Hepatic haematoma 34.80 28.98 12 36608 189 4602183
Normochromic normocytic anaemia 34.77 28.98 22 36598 1444 4600928
Pancreatic neoplasm 34.75 28.98 14 36606 346 4602026
Bicuspid aortic valve 34.74 28.98 12 36608 190 4602182
Peripheral swelling 34.45 28.98 91 36529 26601 4575771
Neurological symptom 34.26 28.98 24 36596 1868 4600504
Peripheral coldness 34.23 28.98 29 36591 2991 4599381
Product commingling 34.19 28.98 11 36609 138 4602234
Orthopnoea 34.17 28.98 21 36599 1309 4601063
Atelectasis 34.12 28.98 33 36587 4042 4598330
Hypospadias 34.02 28.98 18 36602 842 4601530
Microcephaly 33.98 28.98 15 36605 468 4601904
Haemorrhage 33.86 28.98 88 36532 25474 4576898
Pemphigus 33.80 28.98 19 36601 1003 4601369
Foetal distress syndrome 33.78 28.98 18 36602 854 4601518
Pancreatic enzymes increased 33.77 28.98 15 36605 475 4601897
Affect lability 33.66 28.98 31 36589 3571 4598801
Arthritis 33.59 28.98 63 36557 14637 4587735
Intensive care unit acquired weakness 33.55 28.98 11 36609 147 4602225
Blood pressure systolic decreased 33.47 28.98 22 36598 1542 4600830
Hypotonia 33.34 28.98 31 36589 3615 4598757
Hiatus hernia 33.34 28.98 30 36590 3354 4599018
Shock hypoglycaemic 33.31 28.98 10 36610 98 4602274
Generalised tonic-clonic seizure 33.30 28.98 51 36569 10059 4592313
Hydronephrosis 33.28 28.98 28 36592 2861 4599511
Atrioventricular block 33.27 28.98 28 36592 2862 4599510
Cleft lip and palate 33.17 28.98 15 36605 496 4601876
Plasmapheresis 33.02 28.98 11 36609 155 4602217
Hyperinsulinaemia 32.95 28.98 10 36610 102 4602270
Hepatosplenomegaly neonatal 32.92 28.98 7 36613 12 4602360
Macrosomia 32.87 28.98 10 36610 103 4602269
Chromaturia 32.81 28.98 38 36582 5723 4596649
Alcohol poisoning 32.64 28.98 18 36602 915 4601457
Nipple inflammation 32.56 28.98 7 36613 13 4602359
Cellulitis 32.53 28.98 67 36553 16665 4585707
Haemoglobin increased 32.53 28.98 19 36601 1079 4601293
Therapeutic product effect incomplete 32.40 28.98 68 36552 17140 4585232
Diabetic ulcer 32.27 28.98 10 36610 110 4602262
PO2 decreased 32.25 28.98 16 36604 653 4601719
Oxygen consumption decreased 32.11 28.98 10 36610 112 4602260
Hallucination, visual 32.07 28.98 38 36582 5864 4596508
Cardiomegaly 32.06 28.98 35 36585 4942 4597430
Polymerase chain reaction 32.00 28.98 8 36612 36 4602336
Blood lactate dehydrogenase increased 31.85 28.98 43 36577 7560 4594812
Temperature perception test abnormal 31.76 28.98 6 36614 3 4602369
Occult blood positive 31.64 28.98 19 36601 1136 4601236
Diverticulum intestinal 31.62 28.98 20 36600 1312 4601060
Blood magnesium increased 31.58 28.98 13 36607 340 4602032
Hyponatraemic encephalopathy 31.56 28.98 10 36610 119 4602253
Cholecystitis acute 31.32 28.98 24 36596 2145 4600227
Impaired gastric emptying 31.30 28.98 21 36599 1523 4600849
Ectopia cordis 31.29 28.98 7 36613 17 4602355
Hyperhomocysteinaemia 31.07 28.98 9 36611 77 4602295
Insulin-requiring type 2 diabetes mellitus 30.86 28.98 9 36611 79 4602293
Folate deficiency 30.76 28.98 13 36607 364 4602008
Blood folate decreased 30.70 28.98 11 36609 195 4602177
Blood gases abnormal 30.70 28.98 11 36609 195 4602177
Hyperdynamic left ventricle 30.66 28.98 9 36611 81 4602291
Renal artery thrombosis 30.55 28.98 10 36610 133 4602239
Limb injury 30.38 28.98 31 36589 4050 4598322
Cholecystectomy 30.35 28.98 24 36596 2246 4600126
Accidental exposure to product 30.33 28.98 58 36562 13674 4588698
Treatment failure 30.32 28.98 59 36561 14088 4588284
Aortic aneurysm 30.10 28.98 21 36599 1624 4600748
Epstein-Barr virus antibody positive 30.04 28.98 11 36609 208 4602164
Vitamin B1 deficiency 30.00 28.98 9 36611 88 4602284
Epilepsy 29.93 28.98 47 36573 9471 4592901
Angular cheilitis 29.88 28.98 10 36610 143 4602229
Urinary incontinence 29.80 28.98 41 36579 7339 4595033
Deafness neurosensory 29.78 28.98 19 36601 1265 4601107
Urticarial vasculitis 29.73 28.98 9 36611 91 4602281
Onychomycosis 29.68 28.98 17 36603 930 4601442
Mental impairment 29.62 28.98 33 36587 4765 4597607
Balanoposthitis 29.58 28.98 12 36608 302 4602070
Hypochromic anaemia 29.56 28.98 13 36607 402 4601970
Food craving 29.53 28.98 13 36607 403 4601969
Spine malformation 29.51 28.98 10 36610 149 4602223
Pseudomonal sepsis 29.48 28.98 16 36604 788 4601584
Hypophosphataemia 29.38 28.98 26 36594 2843 4599529
Oesophageal obstruction 29.37 28.98 11 36609 222 4602150
Bradyarrhythmia 29.31 28.98 16 36604 797 4601575
Asplenia 29.28 28.98 7 36613 25 4602347
Autoimmune hepatitis 29.17 28.98 25 36595 2619 4599753
Rash pruritic 29.15 28.98 54 36566 12429 4589943
Chills 29.12 28.98 90 36530 28749 4573623
Congenital aortic valve stenosis 29.02 28.98 8 36612 56 4602316
Bladder sphincter atony 29.02 28.98 8 36612 56 4602316
Slow speech 29.00 28.98 14 36606 538 4601834
Orthostatic hypotension 28.98 28.98 39 36581 6835 4595537

Pharmacologic Action:

SourceCodeDescription
ATC A10BA02 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Biguanides
ATC A10BD02 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD03 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD05 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD07 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD08 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD10 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD11 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD13 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD14 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD15 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD16 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD17 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD18 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD20 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD22 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD23 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD25 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
CHEBI has role CHEBI:35526 hypoglycemic agent
FDA EPC N0000175565 Biguanide
FDA CS M0002471 Biguanides
MeSH PA D007004 Hypoglycemic Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Treatment Refractory Type 2 Diabetes Mellitus indication
Gestational diabetes mellitus off-label use 11687002 DOID:11714
Polycystic ovaries off-label use 69878008
Weight loss off-label use 89362005
Prevention of Type 2 Diabetes Mellitus off-label use
Alcoholism contraindication 7200002
Weight gain finding contraindication 8943002
Asthenia contraindication 13791008
Pulmonary edema contraindication 19242006 DOID:11396
Myocardial infarction contraindication 22298006 DOID:5844
Acute vomiting contraindication 23971007
Severe adrenal insufficiency contraindication 24867002
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Dehydration contraindication 34095006
Macular retinal edema contraindication 37231002 DOID:4449
Infectious disease contraindication 40733004
Body fluid retention contraindication 43498006
End stage renal disease contraindication 46177005 DOID:784
Chronic heart failure contraindication 48447003
Lymphocytopenia contraindication 48813009 DOID:614
Hepatic porphyria contraindication 55056006 DOID:3133
Ketoacidosis contraindication 56051008
Acute nephropathy contraindication 58574008
Metabolic acidosis contraindication 59455009
Hepatic failure contraindication 59927004
Hemolytic anemia contraindication 61261009 DOID:583
Glucose-6-phosphate dehydrogenase deficiency anemia contraindication 62403005
Acute infectious disease contraindication 63171007
Osteoporosis contraindication 64859006 DOID:11476
Hypopituitarism contraindication 74728003 DOID:9406
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Lactic acidosis contraindication 91273001 DOID:3650
Fracture of bone contraindication 125605004
Liver function tests abnormal contraindication 166603001
Cobalamin deficiency contraindication 190634004
Angina pectoris contraindication 194828000
Decompensated cardiac failure contraindication 195111005
Acute pancreatitis contraindication 197456007 DOID:2913
Impaired renal function disorder contraindication 197663003
Cerebrovascular accident contraindication 230690007
Disease of liver contraindication 235856003 DOID:409
Drug-induced hepatitis contraindication 235876009
Hypoglycemic disorder contraindication 237630007
Sepsis syndrome contraindication 238150007
Edema contraindication 267038008
Osteopenia contraindication 312894000
Primary adrenocortical insufficiency contraindication 373662000
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Fever contraindication 386661006
Surgical procedure contraindication 387713003
Malignant tumor of urinary bladder contraindication 399326009 DOID:11054
Severe diarrhea contraindication 409587002
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Traumatic injury contraindication 417746004
Fever greater than 100.4 Fahrenheit contraindication 426000000
Radiography with IV Iodinated Contrast Agent contraindication
Prolonged-Severe Nausea and Vomiting contraindication
Severe Hypoxemia contraindication
Severe Autonomic Insufficiency contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.63 Basic
pKa2 3.34 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
1GM XIGDUO XR ASTRAZENECA AB N205649 July 28, 2017 RX TABLET, EXTENDED RELEASE ORAL 6414126 Oct. 4, 2020 TREATMENT OF TYPE 2 DIABETES MELLITUS
1GM XIGDUO XR ASTRAZENECA AB N205649 July 28, 2017 RX TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2020 TREATMENT OF TYPE 2 DIABETES MELLITUS
1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 6936590 Oct. 4, 2020 TREATMENT OF TYPE 2 DIABETES MELLITUS
1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 9198925 Oct. 4, 2020 TREATMENT OF TYPE 2 DIABETES MELLITUS
500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 6414126 Oct. 4, 2020 TREATMENT OF TYPE 2 DIABETES MELLITUS
500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2020 TREATMENT OF TYPE 2 DIABETES MELLITUS
500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 6936590 Oct. 4, 2020 TREATMENT OF TYPE 2 DIABETES MELLITUS
500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 9198925 Oct. 4, 2020 TREATMENT OF TYPE 2 DIABETES MELLITUS
1GM QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 RX TABLET, EXTENDED RELEASE ORAL 6414126 Oct. 4, 2020 TREATMENT OF TYPE 2 DIABETES MELLITUS
1GM QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 RX TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2020 TREATMENT OF TYPE 2 DIABETES MELLITUS
1GM QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 RX TABLET, EXTENDED RELEASE ORAL 6936590 Oct. 4, 2020 TREATMENT OF TYPE 2 DIABETES MELLITUS
1GM QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 RX TABLET, EXTENDED RELEASE ORAL 9198925 Oct. 4, 2020 TREATMENT OF TYPE 2 DIABETES MELLITUS
1GM **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** FORTAMET ANDRX LABS LLC N021574 April 27, 2004 DISCN TABLET, EXTENDED RELEASE ORAL 6790459 March 17, 2021 METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION
500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** FORTAMET ANDRX LABS LLC N021574 April 27, 2004 DISCN TABLET, EXTENDED RELEASE ORAL 6790459 March 17, 2021 METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION
1GM ACTOPLUS MET XR TAKEDA PHARMS USA N022024 May 12, 2009 DISCN TABLET, EXTENDED RELEASE ORAL 6790459 March 17, 2021 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
1GM JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 6699871 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
1GM JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
1GM JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST
1GM JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN
500MG JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 6699871 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
500MG JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
500MG JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST
500MG JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN
1GM JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 6699871 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
1GM JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
500MG JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 6699871 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
500MG JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
1GM KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 RX TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE
1GM KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 RX TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN
500MG KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 RX TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE
500MG KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 RX TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN
1GM QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 RX TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 TREATMENT OF TYPE 2 DIABETES MELLITUS
1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA
1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
1GM KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL 8173663 March 15, 2025 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
500MG KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL 8173663 March 15, 2025 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
1GM JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 7326708 Nov. 24, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
500MG JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 7326708 Nov. 24, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
1GM JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 7326708 Nov. 24, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
500MG JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 7326708 Nov. 24, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 9173859 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 9173859 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 9173859 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9173859 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9173859 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9173859 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
1GM QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 RX TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
1GM KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
500MG KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
1GM JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 8414921 July 21, 2028 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
500MG JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 8414921 July 21, 2028 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
1GM XIGDUO XR ASTRAZENECA AB N205649 July 28, 2017 RX TABLET, EXTENDED RELEASE ORAL 8685934 May 26, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8685934 May 26, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8846695 June 4, 2030 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8846695 June 4, 2030 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8846695 June 4, 2030 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
1GM SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL 8080580 July 13, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
500MG SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL 8080580 July 13, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
1GM SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL 9439902 Oct. 21, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
500MG SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL 9439902 Oct. 21, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL Feb. 1, 2020 NEW CLINICAL DATA ADDED TO THE PRESCRIBING INFORMATION REGARDING CANAGLIFLOZIN ADD-ON COMBINATION THERAPY WITH METFORMIN AND A DIPEPTIDYL-PEPTIDASE-4 INHIBITOR
500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL Feb. 1, 2020 NEW CLINICAL DATA ADDED TO THE PRESCRIBING INFORMATION REGARDING CANAGLIFLOZIN ADD-ON COMBINATION THERAPY WITH METFORMIN AND A DIPEPTIDYL-PEPTIDASE-4 INHIBITOR
1GM KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 RX TABLET, EXTENDED RELEASE ORAL Feb. 27, 2020 PACKAGE INSERT UPDATED WITH RESULTS FROM STUDY CV181168, A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE 3 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF SAXAGLIPTIN ADDED TO DAPAGLIFLOZIN AND METFORMIN
500MG KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 RX TABLET, EXTENDED RELEASE ORAL Feb. 27, 2020 PACKAGE INSERT UPDATED WITH RESULTS FROM STUDY CV181168, A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE 3 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF SAXAGLIPTIN ADDED TO DAPAGLIFLOZIN AND METFORMIN
1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL Oct. 29, 2021 NEW INDICATION FOR CANAGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD)
500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL Oct. 29, 2021 NEW INDICATION FOR CANAGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD)
1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL Oct. 29, 2021 NEW INDICATION FOR CANAGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD)
500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL Oct. 29, 2021 NEW INDICATION FOR CANAGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD)
1GM QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 RX TABLET, EXTENDED RELEASE ORAL May 2, 2022 NEW PRODUCT
1GM SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL Dec. 19, 2022 NEW CHEMICAL ENTITY
500MG SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL Dec. 19, 2022 NEW CHEMICAL ENTITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Mitochondrial complex I (NADH dehydrogenase) Enzyme INHIBITOR CHEMBL CHEMBL
Dipeptidyl peptidase 4 Enzyme IC50 4.54 CHEMBL
5'-AMP-activated protein kinase subunit beta-1 Kinase WOMBAT-PK
Solute carrier family 22 member 3 Transporter Km 2.50 WOMBAT-PK
Solute carrier family 22 member 2 Transporter IC50 3.40 WOMBAT-PK
Solute carrier family 22 member 1 Transporter IC50 2.70 WOMBAT-PK

External reference:

IDSource
4023979 VUID
N0000021984 NUI
C0025598 UMLSCUI
D00944 KEGG_DRUG
786Z46389E UNII
1115-70-4 SECONDARY_CAS_RN
109081006 SNOMEDCT_US
6809 RXNORM
372567009 SNOMEDCT_US
4023979 VANDF
004534 NDDF
d03807 MMSL
965 INN_ID
4091 PUBCHEM_CID
CHEBI:6801 CHEBI
CHEMBL1431 ChEMBL_ID
DB00331 DRUGBANK_ID
CHEMBL1703 ChEMBL_ID
MF8 PDB_CHEM_ID
D008687 MESH_DESCRIPTOR_UI
4779 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
JANUMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-0078 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 19 sections
JANUMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-0080 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 19 sections
JANUMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-0081 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 19 sections
JANUMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-0575 TABLET, FILM COATED 500 mg ORAL NDA 19 sections
JANUMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-0577 TABLET, FILM COATED 1000 mg ORAL NDA 19 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 1 0006-5369 TABLET, FILM COATED 500 mg ORAL NDA 20 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 1 0006-5370 TABLET, FILM COATED 500 mg ORAL NDA 20 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 1 0006-5373 TABLET, FILM COATED 1000 mg ORAL NDA 20 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 1 0006-5374 TABLET, FILM COATED 1000 mg ORAL NDA 20 sections
GLUCOPHAGE HUMAN PRESCRIPTION DRUG LABEL 1 0087-6060 TABLET, FILM COATED 500 mg ORAL NDA 18 sections
GLUCOPHAGE HUMAN PRESCRIPTION DRUG LABEL 1 0087-6063 TABLET, EXTENDED RELEASE 500 mg ORAL NDA 18 sections
GLUCOPHAGE HUMAN PRESCRIPTION DRUG LABEL 1 0087-6064 TABLET, EXTENDED RELEASE 750 mg ORAL NDA 18 sections
GLUCOPHAGE HUMAN PRESCRIPTION DRUG LABEL 1 0087-6070 TABLET, FILM COATED 850 mg ORAL NDA 18 sections
GLUCOPHAGE HUMAN PRESCRIPTION DRUG LABEL 1 0087-6071 TABLET, FILM COATED 1000 mg ORAL NDA 18 sections
Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-7212 TABLET, EXTENDED RELEASE 750 mg ORAL ANDA 13 sections
Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-7267 TABLET, EXTENDED RELEASE 500 mg ORAL ANDA 13 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7455 TABLET, FILM COATED 250 mg ORAL ANDA 13 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7456 TABLET, FILM COATED 500 mg ORAL ANDA 13 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7457 TABLET, FILM COATED 500 mg ORAL ANDA 13 sections
metformin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0185-4416 TABLET, EXTENDED RELEASE 500 mg ORAL ANDA 18 sections
Glyburide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0228-2751 TABLET, FILM COATED 250 mg ORAL ANDA 14 sections
Glyburide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0228-2752 TABLET, FILM COATED 500 mg ORAL ANDA 14 sections
Glyburide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0228-2753 TABLET, FILM COATED 500 mg ORAL ANDA 14 sections
KOMBIGLYZE HUMAN PRESCRIPTION DRUG LABEL 2 0310-6125 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 18 sections
KOMBIGLYZE HUMAN PRESCRIPTION DRUG LABEL 2 0310-6135 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 18 sections
KOMBIGLYZE HUMAN PRESCRIPTION DRUG LABEL 2 0310-6145 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 18 sections
XIGDUO HUMAN PRESCRIPTION DRUG LABEL 2 0310-6225 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 19 sections
XIGDUO HUMAN PRESCRIPTION DRUG LABEL 2 0310-6250 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 19 sections
XIGDUO HUMAN PRESCRIPTION DRUG LABEL 2 0310-6260 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 19 sections
XIGDUO HUMAN PRESCRIPTION DRUG LABEL 2 0310-6270 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 19 sections